|Day Low/High||5.95 / 6.05|
|52 Wk Low/High||1.60 / 6.78|
The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.
Until market conditions shift, I won't be making any sizable buys.
The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Don't trade the headline numbers, but cash in on those traders that do.